Description

Cytarabine (CAS: 147-94-4), also known as Ara-C or Cytosine Arabinoside, is a nucleoside analog and a potent antimetabolite with the molecular formula C₉H₁₃N₃O₅. This white to off-white crystalline powder is widely utilized in oncology research and clinical applications due to its mechanism of action as a DNA synthesis inhibitor. Cytarabine is particularly effective in the treatment of acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), and other hematologic malignancies. It functions by incorporating into DNA during the S-phase of cell division, leading to chain termination and apoptosis of rapidly dividing cells. Our high-purity Cytarabine is rigorously tested for quality, ensuring >98% purity via HPLC analysis, and is supplied in sealed vials under inert gas to maintain stability. Suitable for in vitro and in vivo studies, this product is an essential tool for researchers investigating chemotherapy mechanisms, drug resistance, and combination therapies.

Properties

• CAS Number: 147-94-4
• Complexity: 383
• IUPAC Name: 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one
• InChI: InChI=1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1
• InChI Key: UHDGCWIWMRVCDJ-CCXZUQQUSA-N
• Exact Mass: 243.08552052
• Molecular Formula: C9H13N3O5
• Molecular Weight: 243.22
• SMILES: C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O
• Topological: 129
• Monoisotopic Mass: 243.08552052
• Physical Description: Cytarabine appears as colorless crystals. Used as an antiviral agent.
• Color/Form: Prisms from 50% ethanol
• Odor: ODORLESS
• Melting Point: 414 to 415 °F
• Solubility: >36.5 [ug/mL]
• Stability/Shelf Life: Following reconstitution of the sterile powder with bacteriostatic water for injection containing 0.945% benzyl alcohol, solutions containing 20, 50, or 100 mg of cytarabine per mL have a pH of about 5 and are stable for 48 hours at 20-25 °C; solutions that develop a slight haze should not be used.
• Dissociation Constants: pKa = 4.22
• Synonyms: cytarabine, 147-94-4, Cytosine arabinoside, Aracytidine, Arabinocytidine, Cytarabinoside, Spongocytidine, Aracytin, Cytosar-U, Alexan, Udicil, Arabitin, Cytarabina, Arafcyt, Erpalfa, Cytosine beta-D-arabinofuranoside, arabinocytosine, Citarabina, Cytarabinum, Arabinosylcytosine, Cytarabin, Arabinofuranosylcytosine, Cytosine-beta-D-arabinofuranoside, Cytosinearabinoside, Depocyt (liposomal), beta-D-Arabinosylcytosine, Cytosine arabinofuranoside, Cytosine beta-D-arabinoside, Cytarabinum [INN-Latin], Arabinoside C, 1beta-D-Arabinosylcytosine, Citarabina [INN-Spanish], Cytosine-1-beta-D-arabinofuranoside, Cytosine arabinose, 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone, 1beta-Arabinofuranasylcytosine, Cytosine 1-beta-D-arabinofuranoside, 1beta-D-Arabinofuranosylcytosine, 1-beta-D-Arabinofaranosylcytosine, beta-Arabinosylcytosine, Ara-Cytidine, U 19920A, Beta-cytosine arabinoside, Cytosine-beta-arabinoside, CHX 3311, CCRIS 913, U-19,920, 1-Arabinofuranosylcytosine, 4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one, Arabinofuranosyl Cytidine, Cytosine, 1-beta-D-arabinosyl-, 1-beta-D-Arabinosylcytosine, HSDB 3049, 1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, EINECS 205-705-9, 1-(arabinofuranosyl)cytosine, Cyclocide, Cytosine, 1-beta-D-arabinofuranosyl-, NSC 287459, UNII-04079A1RDZ, 1-beta-arabinofuranosylcytosine, U-19920, DTXSID3022877, CHEBI:28680, AI3-52329, 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin, 04079A1RDZ, 2(1H)-Pyrimidinone, 4-amino-1-beta-D-arabinofuranosyl-, NSC-287459, MK 8242, 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon, DTXCID702877, NCI-C04728, VYXEOS COMPONENT CYTARABINE, 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine, AC-1075, Cytarabine [USAN:USP:INN:BAN:JAN], Cytarbel, (Arabinofuranosyl)cytosine, Cytarabinum (INN-Latin), Citarabina (INN-Spanish), CYTARABINE (MART.), CYTARABINE [MART.], CYTARABINE (USP-RS), CYTARABINE [USP-RS], Citozar, ara-Cytosine, Tarabine PFS, CYTARABINE (EP MONOGRAPH), CYTARABINE (USP IMPURITY), CYTARABINE [EP MONOGRAPH], CYTARABINE [USP IMPURITY], Cytosine-1-beta-arabinofuranoside, CYTARABINE (USP MONOGRAPH), CYTARABINE [USP MONOGRAPH], Ara-cell, Cytarabine (USAN:USP:INN:BAN:JAN), Arabinoside, Cytosine, Arabine, 1-(beta-d-arabinofuranosyl)cytosine, U-19920 A, cytarabine ocphosphate, U 19920, 2(1H)-Pyrimidinone, 4-amino-1beta-D-arabinofuranosyl-, BETA-CYTOSINE, ARABINOSIDE, L01BC01, 1(BETA-D-ARABINOFURANOSYL)CYTOSINE, WR-28453, U 19,920A, U 19,920, 1-BETA-D-ARABINOSYL-4-AMINO-2(1H)PYRIMIDINONE, 205-705-9, Ara-C, Depocyt, Aracytine, Tarabine, DepoCyte, 1-beta-D-Arabinofuranosylcytosine, Cytosar, 4-Amino-1-((2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one, AraC, Iretin, cytarabine liposome, Cytosine |A-D-Arabinofuranoside, MFCD00066487, (beta-D-Arabinofuranosyl)cytosine, CHEMBL803, 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydropyrimidin-2-one, C9H13N3O5, 2(1H)-Pyrimidinone, 4-amino-1-.beta.-D-arabinofuranosyl-, AR3, Cytonal, 1-beta-D-arabinofuranosyl-cytosine, beta-Ara C, 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one, NCGC00093356-03, 2(1H)-Pyrimidinone, 4-amino-1-y-D-arabinofuranosyl- [CAS], Cytosine arabinoside (VAN), cytarabine liposome injection, Arabinosyl Cytosine, Cytosine, beta-D-arabinoside, CAS-147-94-4, SMR000449317, Depocyt (TN), Cytartbine, 1-.beta.-D-Arabinofuranosylcytosine, Cytarabine; 4-amino-1-beta-d-arabinofuranosylpyrimidin-2(1H)-one, SR-01000075773, NSC287459, 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech], 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech], 1-.beta.-D-arabinofuranosyl-cytosine, 4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone, 1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside, Cytarabine (Standard), beta -arabinosylcytosine, Arabinofuranosylcytosine?, CYTARABINE [MI], CYTARABINE [INN], CYTARABINE [JAN], CYTARABINE [HSDB], CYTARABINE [USAN], beta -cytosine arabinoside, beta -D-arabinosylcytosine, Cytosine-beta -arabinoside, CYTARABINE [VANDF], SCHEMBL3140, 1beta -D-Arabinosylcytosine, CYTARABINE [WHO-DD], CYTARABINE [WHO-IP], BIDD:PXR0139, Lopac0_000316, MLS000758310, MLS001066340, MLS001424023, 1-beta-D-Arabinosyl-Cytosine, BIDD:GT0371, CYTARABINE [EMA EPAR], Cytosine, beta -D-arabinoside, 1beta -Arabinofuranasylcytosine, Cytarabine (JP18/USP/INN), Cytarabine – Bio-X trade mark, GTPL4827, 1-ss-D-Arabinofuranosylcytosine, CYTARABINE [ORANGE BOOK], SCHEMBL22591193, SCHEMBL23152019, 1beta -D-Arabinofuranosylcytosine, Cytosine, 1-beta -D-arabinosyl-, 1-beta -d-arabinofuranosylcytosine, 1-beta-D-arabinofuranosyl cytosine, Cytosine-beta -D-arabinofuranoside, HMS2051K19, HMS2090A18, HMS2230M16, HMS3713N12, 1-beta -D-Arabinofaranosylcytosine, CYTARABINE LIPOSOME [VANDF], CYTARABINUM [WHO-IP LATIN], BCP02876, Tox21_111203, Tox21_301971, BDBM50087289, CCG-51297, HY-13605R, s1648, AKOS007930145, AKOS015896896, Cytosine, 1-beta -D-arabinofuranosyl-, DB00987, KS-5063, NA05771, NC00070, SDCCGSBI-0050304.P002, NCGC00093356-04, NCGC00093356-05, NCGC00093356-06, NCGC00093356-19, NCGC00142483-02, NCGC00255381-01, BA164339, HY-13605, SRI-10828-19, SRI-10828-20, SRI-10828_24, SL-000002, C2035, NS00005949, SW197450-5, C02961, D00168, EN300-118320, 1-BETA-D-ARABINOFURANOSYLCYTOSINE; ARA-C, Q180983, SR-01000721860, SR-01000075773-3, SR-01000075773-5, SR-01000721860-6, 1-beta -D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl, BRD-K33106058-001-07-7, BRD-K33106058-001-16-8, BRD-K33106058-003-20-6, 2(1H)-Pyrimidinone, 4-amino-1beta -D-arabinofuranosyl-, Cytosine -D-arabinofuranoside;Cytosine Arabinoside;Ara-C, Z1511499171, 2(1H)-Pyrimidinone, 4-amino-1-beta -D-arabinofuranosyl-, Cytarabine, European Pharmacopoeia (EP) Reference Standard, Cytarabine, United States Pharmacopeia (USP) Reference Standard, Cytosine beta-D-arabinofuranoside, crystalline, >=90% (HPLC), Cytosine beta-D-arabinofuranoside, Vetec(TM) reagent grade, 90%, Cytarabine, Pharmaceutical Secondary Standard; Certified Reference Material, Cytosine-b-D-arabinofuranoside;4-Amino-1-(b-D-Arabinofuranosyl)-2(1H)pyrimidinone, 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one, Cytosine -D-arabinofuranoside hydrochloride;Cytosine Arabinoside hydrochloride;Ara-C hydrochloride, Cytosine-b-D-arabinofuranoside;1-(b-D-Arabinofuranosyl)cytosine;4-Amino-1-(b-D-Arabinofuranosyl)-2(1H)pyrimidinone

Cytarabine is primarily used in research and clinical settings for its antineoplastic properties. It is a cornerstone in chemotherapy regimens for leukemias and lymphomas, often administered via intravenous or intrathecal routes. Researchers employ Cytarabine to study cell cycle arrest, DNA damage response, and apoptosis pathways. Its liposomal formulation (e.g., Depocyt) is investigated for sustained-release applications in meningeal leukemia. Additionally, Cytarabine serves as a reference standard in pharmacokinetic and pharmacodynamic studies.

Safety and Hazards

GHS Hazard Statements

• H317 (58.7%): May cause an allergic skin reaction [Warning Sensitization, Skin]
• H340 (40%): May cause genetic defects [Danger Germ cell mutagenicity]
• H360 (40%): May damage fertility or the unborn child [Danger Reproductive toxicity]
• H361 (56%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]

Precautionary Statements

• P203, P261, P272, P280, P302+P352, P318, P321, P333+P317, P362+P364, P405, and P501

Hazard Classes and Categories

• Skin Sens. 1 (58.7%)
• Muta. 1B (40%)
• Repr. 1B (40%)
• Repr. 2 (56%)

If you are interested or have any questions, please contact us at support@atomfair.com

Disclaimer: Sold exclusively for laboratory research. Prohibited for commercial use, diagnostics, or human/animal applications. Buyers assume all compliance liability.